111 related articles for article (PubMed ID: 33468932)
21. [A Case of Advanced Breast Cancer in Which Marked Improvement of Joint Pain Was Obtained with Stepwise Dose Reduction of Trastuzumab Emtansine (T-DM1)].
Yabe N; Murai S; Harada Y; Yokose T; Yokoe T; Oto I; Yoshikawa T; Kitasato K; Shimizu H; Jinno H; Kitagawa Y
Gan To Kagaku Ryoho; 2015 Nov; 42(12):1818-20. PubMed ID: 26805183
[TBL] [Abstract][Full Text] [Related]
22. [Combination Therapy of Bevacizumab plus Paclitaxel Was Effective for a Metastatic Choroidal Tumor Secondary to Breast Cancer in a Patient with Ocular Symptoms].
Hattori M; Shirahane K; Sakai M; Sassa Y; Nishihara Y; Aibe H; Masuda M; Mori D
Gan To Kagaku Ryoho; 2020 Aug; 47(8):1221-1224. PubMed ID: 32829359
[TBL] [Abstract][Full Text] [Related]
23. UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer.
Campone M; Lacroix-Triki M; Roca L; Spielmann M; Wildiers H; Cottu P; Kerbrat P; Levy C; Desmoulins I; Bachelot T; Winston T; Eymard JC; Uwer L; Duhoux FP; Verhoeven D; Jaubert D; Coeffic D; Orfeuvre H; Canon JL; Asselain B; Martin AL; Lemonnier J; Roché H
Eur J Cancer; 2018 Nov; 103():184-194. PubMed ID: 30267987
[TBL] [Abstract][Full Text] [Related]
24. [A case of triple negative chest wall recurrent breast cancer treated with capecitabine and docetaxel combination therapy (XT therapy)].
Sawada Y; Fujii T; Takahashi H; Yokoyama G; Matsubayashi RN; Inoue Y; Uesugi N; Momosaki S; Toh U; Shirouzu K
Gan To Kagaku Ryoho; 2009 May; 36(5):815-7. PubMed ID: 19461184
[TBL] [Abstract][Full Text] [Related]
25. [A case of chest wall recurrence after mastectomy for breast cancer that showed response to chemotherapy].
Hasegawa K; Matsui T; Aoyagi H; Yoshida T; Kaneko J; Maejima S
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2378-80. PubMed ID: 24394118
[TBL] [Abstract][Full Text] [Related]
26. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
27. [Two cases of recurrence of breast cancer at the chest wall wherein chest wall complications were treated by ablation].
Yoshitomi S; Tsuji H; Abe Y
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2348-50. PubMed ID: 24394108
[TBL] [Abstract][Full Text] [Related]
28. [Case Report of Long-Term Clinical Efficacy of Paclitaxel plus Bevacizumab Combination Therapy for Stage Ⅳ AdvancedBreast Cancer].
Sugimoto H; Miura T; Kawamura Y; Aburatani T; Hanaoka M; Ogo T; Hoshino N; Nishioka Y; Kawano T
Gan To Kagaku Ryoho; 2019 Dec; 46(13):2246-2248. PubMed ID: 32156893
[TBL] [Abstract][Full Text] [Related]
29. [A Case of Locally Advanced and Metastatic Breast Cancer Treated with Preoperative Bevacizumab Combination Chemotherapy That Attained Local Control].
Watanabe N; Furukawa J; Minoji T; Tamai K; Kitahara T; Yamamura N; Okamura S; Fukuchi N; Ebisui C; Yokouchi H; Kinuta M
Gan To Kagaku Ryoho; 2018 Jul; 45(7):1097-1099. PubMed ID: 30042280
[TBL] [Abstract][Full Text] [Related]
30. [An elderly advanced breast cancer with a good response to anastrozole].
Matsui K; Tazawa K; Karato M; Nagata T; Shimada Y; Tsukada K
Gan To Kagaku Ryoho; 2010 Aug; 37(8):1557-60. PubMed ID: 20716886
[TBL] [Abstract][Full Text] [Related]
31. [A Long-Surviving Case of HER2-Positive Breast Cancer with Brain Metastasis Treated through Multidisciplinary Therapy].
Nakakuma T; Takahashi K; Ueno S; Kondou Y; Kosaka Y; Sengoku N
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1107-1109. PubMed ID: 29394549
[TBL] [Abstract][Full Text] [Related]
32. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
Gligorov J; Doval D; Bines J; Alba E; Cortes P; Pierga JY; Gupta V; Costa R; Srock S; de Ducla S; Freudensprung U; Mustacchi G
Lancet Oncol; 2014 Nov; 15(12):1351-60. PubMed ID: 25273343
[TBL] [Abstract][Full Text] [Related]
33. Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer.
Takada K; Kashiwagi S; Goto W; Asano Y; Takahashi K; Takashima T; Tomita S; Ohsawa M; Hirakawa K; Ohira M
J Transl Med; 2018 Apr; 16(1):86. PubMed ID: 29615076
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
35. Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905).
Kim HR; Jung KH; Im SA; Im YH; Kang SY; Park KH; Lee S; Kim SB; Lee KH; Ahn JS; Kim SI; Sohn JH
Ann Oncol; 2013 Jun; 24(6):1485-90. PubMed ID: 23380385
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
von Minckwitz G; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Kreienberg R; Solbach C; Gerber B; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Fehm T; Müller BM; Denkert C; Loibl S; Nekljudova V; Untch M; ;
N Engl J Med; 2012 Jan; 366(4):299-309. PubMed ID: 22276820
[TBL] [Abstract][Full Text] [Related]
37. [A Case of Locally Advanced Breast Cancer Successfully Treated with Local Control That Achieved a Pathological Complete Response after Bevacizumab and Paclitaxel Combination Chemotherapy].
Ueno N; Suzushino S; Kubo T; Abe A; Ito J; Yasuda M; Kato H
Gan To Kagaku Ryoho; 2017 Nov; 44(11):1033-1035. PubMed ID: 29138383
[TBL] [Abstract][Full Text] [Related]
38. [A patient with advanced breast cancer refractory to chemotherapy accompanied by carcinomatous pleurisy and multiple bone metastasis that responded to combination therapy with high-dose toremifene and docetaxel].
Suzuki M
Gan To Kagaku Ryoho; 2007 Jan; 34(1):69-72. PubMed ID: 17220673
[TBL] [Abstract][Full Text] [Related]
39. A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01).
Hurvitz SA; Allen HJ; Moroose RL; Chan D; Hagenstad C; Applebaum SH; Patel G; Hu EH; Ryba N; Lin LS; Wang H; Glaspy J; Slamon DJ; Kabbinavar F
Clin Breast Cancer; 2010 Aug; 10(4):307-12. PubMed ID: 20705564
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study.
Greil R; Moik M; Reitsamer R; Ressler S; Stoll M; Namberger K; Menzel C; Mlineritsch B
Eur J Surg Oncol; 2009 Oct; 35(10):1048-54. PubMed ID: 19250795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
